Immunogenic compositions for use in pneumococcal vaccines
An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae , in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
1. A method of treating or ameliorating an infection, disease or condition caused by Streptococcus pneumoniae serotype 9N, 9A and/or 9L in a human subject, comprising administering to the human subject an immunologically effective amount of an immunogenic composition comprising
glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F, and
wherein said immunogenic composition does not comprise capsular saccharide from S. pneumoniae serotype 9N, 9A and 9L.
2. The method of claim 1 , wherein each of said glycoconjugates are individually conjugated to a carrier protein.
3. The method of claim 1 , wherein each of said glycoconjugates comprises S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F individually conjugated to CRM 197 .
4. The method of claim 1 , wherein each of said glycoconjugates comprises S. pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14 and/or 23F individually conjugated to Haemophilus influenzae protein D (PD).
5. The method of claim 1 , wherein the glycoconjugate from S. pneumoniae serotype 18C is conjugated to tetanus toxoid (TT).
6. The method of claim 1 , wherein the glycoconjugate from S. pneumoniae serotype 19F is conjugated to diphtheria toxoid (DT).